On April 26, 2024, the Food and Drug Administration inspected TMRW Biorepository New York, LLC in New York concerning its human cellular, tissue, and gene therapy operations, according to data posted on the FDA’s website.
The final FDA report stated that TMRW Biorepository New York, LLC was not required to implement any corrective actions related to its management practices.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
According to its website, the FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety and quality.
Information in this article was obtained from the U.S. Food and Drug Administration. The source data can be found here.
